Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors during the central nervous program, conolidine modulates alternate molecular targets. A Science Improvements research found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://peterd863ayo8.popup-blog.com/profile